Barclays Public Limited Com invested 0% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP).
Looking forward, the company is expected to report earnings of $0.12 per share for the current quarter.
The counter witnessed a trading volume of 0.42 million shares versus an average volume of 0.48 million shares during last trading session.
HZNP has been the topic of several analyst reports.
Horizon Pharma plc (HZNP) traded with the volume of 4.45 Million shares while its average 3 months volume is at 3860 shares. Horizon Pharma Plc now has $1.73 billion valuation. They now have a United States dollars 17 price target on the stock.
Amid volatile financial markets and the presidential election, various investment brokerages have made amendments to their price targets and ratings on shares of Flex Pharma, Inc. The recommendation scale measures the value from 1 to 5, where 1 means "Strong Buy" and 5 stands for "Sell". Horizon Pharma PLC presently has an average rating of "Buy" and an average price target of $21.38.
Horizon Pharma Ord (NASDAQ:HZNP) shares traded 1.02% up during most recent session to reach at the closing price of $10.94.
Debt to Equity ratio stands at 1.57 while Long Term Debt To Equity Ratio flashes the value of 1.56. The firm's 50 day moving average is $14.02 and its 200-day moving average is $16.26. Horizon Pharma PLC has a 12 month low of $9.45 and a 12 month high of $23.44. The biopharmaceutical company reported $0.21 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.25 by $0.04. US Bancorp DE boosted its stake in Horizon Pharma PLC by 1.2% in the first quarter. The firm had revenue of $220.90 million during the quarter, compared to the consensus estimate of $248.71 million. During the same period in the prior year, the firm posted $0.34 EPS. The company's revenue was up 7.9% compared to the same quarter previous year. On average, equities analysts expect that Horizon Pharma PLC will post $0.85 earnings per share for the current fiscal year.
Also, Director Michael G. Grey bought 10,000 shares of Horizon Pharma PLC stock in a transaction dated Wednesday, May 10th. Its last month's stock price volatility remained 6.11% which for the week stands at 3.88%. The stock was sold at an average price of $16.03, for a total transaction of $509,882.24. The disclosure for this sale can be found here. 4,131,231 shares of the company's stock were exchanged. It dropped, as 89 investors sold PG shares while 777 reduced holdings. The correct version of this report can be viewed at https://transcriptdaily.com/2017/05/17/ubs-asset-management-americas-inc-cuts-stake-in-horizon-pharma-plc-hznp-updated-updated.html. Bank of New York Mellon Corp now owns 750,930 shares of the biopharmaceutical company's stock worth $13,614,000 after buying an additional 51,860 shares during the last quarter.
07/14/2016 - Horizon Pharma, Inc. had its "buy" rating reiterated by analysts at Brean Capital. The firm owned 165,260 shares of the biopharmaceutical company's stock after buying an additional 2,620 shares during the period. First Trust Advisors LP bought a new stake in shares of Horizon Pharma PLC during the third quarter worth approximately $522,000. Finally, BlackRock Advisors LLC boosted its position in Horizon Pharma PLC by 39.3% in the third quarter. First Mercantile Trust Co. now owns 11,770 shares of the biopharmaceutical company's stock valued at $174,000 after buying an additional 310 shares in the last quarter. Finally, Fort Point Capital Partners LLC raised its stake in shares of Horizon Pharma PLC by 59.3% in the first quarter. The institutional investor owned 244,533 shares of the biopharmaceutical company's stock after selling 461,399 shares during the period.
COPYRIGHT VIOLATION NOTICE: "Graybill Bartz & Assoc Ltd. Increases Stake in Horizon Pharma PLC (HZNP)" was reported by BBNS and is owned by of BBNS. If you are viewing this article on another publication, it was copied illegally and republished in violation of US and worldwide copyright and trademark legislation.
Horizon Pharma Public Limited Company is a biopharmaceutical company.